Katalin Karikó: h-index, Total Citations, and Citation Map
Katalin Karikó's h-index is 67 (111 i10-index, 34,925+ total citations across 228+ publications) according to Google Scholar as of July 2026. Katalin Karikó is affiliated with BioNTech RNA Pharmaceuticals.
Katalin Karikó is a researcher affiliated with BioNTech RNA Pharmaceuticals, specializing in mRNA-based therapy for protein replacement. Their work has been cited 34,925 times. This profile visualizes their global influence, highlighting strong citation networks in United States.
Katalin Karikó's Citation Metrics
Bibliometric impact based on 228 indexed publications.
- H-Index
- 67
- i10-Index
- 111
- Total Citations
- 34,925
- Citing Countries
- 56
As of July 2026.
Katalin Karikó has an h-index of 67 and 34,925 total citations across 228 publications, with research cited by institutions in 56 countries.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA
20053,264
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Significant Contributions
Auto-detected research lines — a seminal paper and the follow-up work building on it. Review and edit before using in a petition. Each Free PDF opens in a new tab — EB-1A organises this into the structure USCIS applies to Criterion 5 of 8 CFR § 204.5(h)(3)(v); EB-1B re-frames it under § 204.5(i)(3) (outstanding researcher); NIW presents it under prong 2 of Matter of Dhanasar.
1162 citing papers could not be classified (no author data) — excluded from the percentages above.
The researcher established foundational principles of RNA immunogenicity and nucleoside modification, enabling the development of non-immunogenic mRNA therapeutics with enhanced stability and translational capacity.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
About Katalin Karikó's research
Katalin Karikó is a researcher in mRNA-based therapy for protein replacement at BioNTech RNA Pharmaceuticals. Their work has been cited 34,925 times across 228 publications (h-index 67), according to Google Scholar.
Their most-cited work, “Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA” (2005), has accumulated 3,264 citations. Other influential works include “mRNA-based therapeutics—developing a new class of drugs” (2014) with 3,048 citations and “Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability” (2008) with 2,555 citations.
Citations of Katalin Karikó's research come primarily from United States, China and Germany, reflecting international research impact across 5+ countries. The interactive citation map above shows the full geographic distribution of the institutions citing this work.
